|
黄琳 |
|
|
主任药师、副教授、学硕导师，药学院专硕导师在岗 |
|
|
研究领域：药物个体化应用研究、药物不良反应机制研究 |
|
|
电话：（010）88325750 |
|
|
教育背景 |
|
|
华中科技大学同济医学院医学博士（2008） |
|
|
华中科技大学同济医学院医学学士（2004） |
|
|
|
|
|
工作经历 |
|
|
2024.11至今 北京大学人民医院药学部，副主任 |
|
|
2022.08至今 北京大学人民医院药学部，党支部书记 |
|
|
2020.08至今 北京大学人民医院药剂科，副教授 |
|
|
2018.12至今 北京大学人民医院药剂科，学科助理/临床药学组长 |
|
|
2017.10-2018.09 美国匹兹堡大学药学院，高级访问学者 |
|
|
2017.08至今 北京大学人民医院药剂科，主任药师 |
|
|
2012.08-2017.07 北京大学人民医院药剂科，副主任药师 |
|
|
2008.08-2012.07 北京大学人民医院药剂科，主管药师 |
|
|
|
|
|
社会兼职 |
|
|
中国研究型医院学会药物经济学专委会常务委员 中国研究型医院学会儿科学专委会委员 中国医药教育协会老年药学专委会委员 中国心胸血管麻醉学会心血管药学分会委员 北京大学治疗药物监测和临床毒理中心专家委员会副主任委员 北京医学会临床药学分会委员 北京药学会临床研究与转化专业委员会委员 《中国药房杂志》编委、《药物不良反应杂志》通讯编委 |
|
|
|
|
|
代表性论文 |
|
|
1.Yuanyuan Li*, Nan Guo*, Yinyu Zhao, Jiali Chen, Jinxia Zhao, Jialu Bian, Jing Guo, Changqing Yang, Xiaohong Zhang, Lin Huang#. IL-17A Activates JAK/STAT Signaling to Affect Drug Metabolizing Enzymes and Transporters in HepaRG Cells [J]. Molecular Immunology, 2024 Nov:175:55-62. 2.Yinyu Zhao, Nan Guo, Yidan Zhu, Jingyuan Shang, Jiali Chen, Xingxian Luo, Yi Liu, Xiaohong Zhang#, Lin Huang#. Population pharmacokinetic models of venetoclax in hematologic malignancies: A systematic review [J]. Drug Design Development and Therapy, 2024 May 27: 18: 1771-1784. 3.Yuanyuan Li#, Ying Zhang#, Jinxia Zhao, Jialu Bian, Yinyu Zhao, Xu Hao, Boyu Liu, Lei Hu, Fang Liu, Changqing Yang, Yufei Feng#, Lin Huang#.Combined Impact of Hypoalbuminemia and Pharmacogenomic Variants on Voriconazole Trough Concentration： data from a real-life clinical setting in the Chinese population [J]. Journal of Chemotherapy, 2024 May;36(3):179-189. 4.Xu Hao*, Yuanyuan Li*, Ying Zhang, Jialu Bian, Jinxia Zhao, Yinyu Zhao, Lei Hu, Xingxian Luo, Changqing Yang, Yufei Feng, Lin Huang#. Individualized treatment with voriconazole in the Chinese population: inflammation level as a novel marker for dose optimization [J]. British Journal of Clinical Pharmacology, 2024 Feb; 90(2): 440-451. 5.Xingxian Luo*, Lin Huang*, Xin Du*, Yue Yang, Xufeng Lv, Xiaohong Zhang#. Current regulatory status in China of drugs withdrawn from the US FDA accelerated pathway: implications for regulation globally. [J]. Lancet oncology. 2024;25(6):703-706. 6.Xingxian Luo*, Xin Du*, Xufeng Lv, Yue Yang, Xiaohong Zhang#, Lin Huang#. Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024. JAMA Netw Open. 2024 Oct 1;7(10):e2439080. 7.Xingxian Luo, Yang Xu, Xin Du, Xufeng Lv, Si Chen, Yue Yang#, Lin Huang#, Xiaohong Zhang#. Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China. Lancet Reg Health West Pac. 2024 Nov 7;52:101238. 8.Chaoqun Ma , Xiaolei Ren , Pang Ning , Liu Yingkun , Chen Meifang , Zhang Xiaohong , Liu Yi# , Lin Huang#. Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 10. 9.Chunyan Zhang, Xiaolei Ren, Jing Huang, Lin Huang#, Xiaohong Zhang#. Central serous chorioretinopathy secondary to systemic corticosteroids: a case report and review of the literature. [J]. Expert Opin Drug Saf. 2024, Aug 2: 1-5. 10.Xia Si, Hongyan Zhang, Qingming Ding, Gang Liu, Lin Huang#, Xin Sun#. Retrospective analysis of real-world prescribing data for managing cisplatin-based chemotherapy-induced nausea and vomiting in China [J]. Cancer Med 2024 Mar;13(6): e7121. 11.Chunyan Zhang*, Xiaolei Ren*, Liu Yi, Lin Huang#, Yufei Feng, Zhang Xiaohong#. Effects of Wuzhi Capsule on Whole-Blood Tacrolimus Concentration Levels: A Systematic Review and Meta-Analysis. Ther Drug Monit. 2024 Feb 1;46(1):33-41.
|
|
|
荣誉奖励 |
|
|
2016-2017年度中华医学会临床药学分会优秀临床药师 2013-2014年度北京药学会临床药学之星 2013-2014、2016-2017、2019-2020、2020-2021年度北京大学人民医院优秀共产党员 |
|